GlassScriptPhysician profile
Jenny S Oh
NPI 1386657856
$26,114.65
in general payments reported to CMS, 2019-2025
46 companies · $3,762 in 2025
The $3,762 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $2,653 · 2021: $2,457 · 2022: $3,408 · 2023: $5,189 · 2024: $5,833 · 2025: $3,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,620 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Education: $88.60 · Travel and Lodging: $25.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,948.80 |
| Consulting Fee | $1,620.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Education | $88.60 |
| Travel and Lodging | $25.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,854.71 | 2019-2025 | |
| Amgen INC. | $4,263.89 | 2019-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $3,546.01 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $3,134.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,332.24 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,043.91 | 2019-2024 | Taltz, Olumiant |
| Radius Health, INC. | $893.05 | 2019-2025 | Tymlos |
| Pfizer INC. | $712.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $693.99 | 2021-2025 | Saphnelo |
| Ucb, INC. | $534.08 | 2019-2025 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $476.75 | 2019-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $463.68 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $462.85 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.11 | 2022-2025 | Ofev, Cyltezo, Spevigo |
| Mallinckrodt Hospital Products INC. | $335.10 | 2020-2024 | Acthar |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $324.79 | 2022-2025 | Lupkynis |
| Celgene Corporation | $317.78 | 2019 | |
| Hikma Pharmaceuticals USA | $290.93 | 2019-2022 | |
| Octapharma USA, INC. | $267.10 | 2021-2025 | Octagam Immune Globulin (Human), Panzyga |
| Organon LLC | $233.16 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Mallinckrodt Enterprises LLC | $227.36 | 2019 | |
| Ani Pharmaceuticals, INC. | $200.11 | 2024-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $199.24 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Genzyme Corporation | $170.90 | 2019-2020 | |
| Depuy Synthes Sales INC. | $108.81 | 2021-2024 | Monovisc, Orthovisc |
| Sanofi-Aventis U.S. LLC | $88.60 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $79.37 | 2024 | Arcalyst |
| Janssen Scientific Affairs, LLC | $56.55 | 2025 | |
| Invivyd INC | $51.82 | 2025 | Pemgarda |
| Sobi, INC | $49.43 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.90 | 2019-2021 | |
| Kyowa Kirin, INC. | $37.05 | 2023 | Crysvita |
| Gilead Sciences, INC. | $29.84 | 2019 | |
| Alvogen INC | $29.80 | 2025 | Teriparatide |
| Novo Nordisk INC | $26.23 | 2025 | Wegovy, Saxenda |
| Scilex Pharmaceuticals INC. | $22.48 | 2024 | |
| Angiodynamics, INC. | $21.42 | 2021 | |
| Zimmer Biomet Holdings, INC. | $20.97 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Pacira Therapeutics, INC. | $20.23 | 2021 | |
| Eisai INC. | $18.51 | 2023 | |
| Genentech USA, INC. | $18.33 | 2024 | Actemra |
| Teva Pharmaceuticals USA, INC. | $16.39 | 2024 | Simlandi |
| Vertiflex, INC. | $16.22 | 2019 | |
| Bioventus LLC | $15.37 | 2022 | |
| Tactile Systems Technology INC | $13.22 | 2019 | |
| Medexus Pharma, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.